J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies

Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared…

Read More

With RFK Jr. in Charge, Supplement Makers See Chance To Cash In

Last fall, before being named the senior U.S. health official, Robert F. Kennedy Jr. said the Trump administration would liberate Americans from the FDA’s “aggressive suppression” of vitamins, dietary supplements, and other substances — ending the federal agency’s “war on public health,” as he put it. In fact, the FDA can’t even require that supplements…

Read More